Evidence map›Paper›PMID 34878723›Full record

ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2022

Cytoskeletal protein degradation in brain death donor kidneys associates with adverse posttransplant outcomes.

Rebecca H Vaughan, Jean-Claude Kresse, Louise K Farmer, Marie L Thézénas, Benedikt M Kessler, Jan H N Lindeman, Edward J Sharples, Gavin I Welsh, Rikke Nørregaard, Rutger J Ploeg and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Cytoskeletal protein degradation in brain death donor kidneys associates with adverse posttransplant outcomes.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Rebecca H VaughanResearch and Development, NHS Blood and Transplant, Bristol & Oxford, UK.
Jean-Claude KresseDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Louise K FarmerBristol Renal, Bristol Medical School, University of Bristol, Bristol, UK.
Marie L ThézénasNuffield Department of Medicine, Target Discovery Institute, University of Oxford, Oxford, UK.
Benedikt M KesslerNuffield Department of Medicine, Target Discovery Institute, University of Oxford, Oxford, UK.ORCID 0000-0002-8160-2446
Jan H N LindemanDepartment of Surgery, Leiden University Medical Centre, Leiden, The Netherlands.
Edward J SharplesOxford University Hospital, Oxford, UK.
Gavin I WelshBristol Renal, Bristol Medical School, University of Bristol, Bristol, UK.ORCID 0000-0002-2148-6658
Rikke NørregaardDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.ORCID 0000-0002-0580-373X
Rutger J PloegResearch and Development, NHS Blood and Transplant, Bristol & Oxford, UK.ORCID 0000-0001-7801-665X
Maria KaisarResearch and Development, NHS Blood and Transplant, Bristol & Oxford, UK.ORCID 0000-0002-0712-9937
University of Oxford · GBAarhus University · DKLeiden University · NLNHS Blood and Transplant · GBUniversity of Bristol · GB

Funding

Medical Research Council MR/R014132/1
6 · The paper itself

Abstract

In brain death, cerebral injury contributes to systemic biological dysregulation, causing significant cellular stress in donor kidneys adversely impacting the quality of grafts. Here, we hypothesized that donation after brain death (DBD) kidneys undergo proteolytic processes that may deem grafts susceptible to posttransplant dysfunction. Using mass spectrometry and immunoblotting, we mapped degradation profiles of cytoskeletal proteins in deceased and living donor kidney biopsies. We found that key cytoskeletal proteins in DBD kidneys were proteolytically cleaved, generating peptide fragments, predominantly in grafts with suboptimal posttransplant function. Interestingly, α-actinin-4 and talin-1 proteolytic fragments were detected in brain death but not in circulatory death or living donor kidneys with similar donor characteristics. As talin-1 is a specific proteolytic target of calpain-1, we investigated a potential trigger of calpain activation and talin-1 degradation using human ex vivo precision-cut kidney slices and in vitro podocytes. Notably, we showed that activation of calpain-1 by transforming growth factor-β generated proteolytic fragments of talin-1 that matched the degradation fragments detected in DBD preimplantation kidneys, also causing dysregulation of the actin cytoskeleton in human podocytes; events that were reversed by calpain-1 inhibition. Our data provide initial evidence that brain death donor kidneys are more susceptible to cytoskeletal protein degradation. Correlation to posttransplant outcomes may be established by future studies.

Indexed as

Kidney TransplantationTissue and Organ ProcurementBrain DeathCytoskeletal ProteinsGraft SurvivalHumansKidneyLiving DonorsProteolysisTissue DonorsCytoskeletal Proteinsbasic (laboratory) research/sciencecellular biologydonors and donation: donation after brain death (DBD)glomerular biology and diseasekidney (allograft) function/dysfunctionkidney failure/injurykidney transplantation/nephrologyorgan transplantation in generalproteomicsQUOD biobanktranslational research/science

Identifiers

PMID34878723
PMCPMC9305475
OpenAlexW4200170658

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.